全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
Iatreia  2012 

Beneficios de la terapia con hidroxiúrea en ni?os con anemia de células falciformes

Keywords: hospitalization, hydroxyurea, sickle cell anemia, toxicity, transfusion.

Full-Text   Cite this paper   Add to My Lib

Abstract:

objective: to assess the toxicity and benefits of hydroxyurea (hu) in the management of children with sickle cell disease (scd). materials and methods: a descriptive observationalretrospective study of patients with scd treated with hu was carried out at hospital pablo tobón uribe in medellin, colombia, from may 2004 to september 2009. sixteen patients aged under 15 years were treated with this drug; out of them, 11 (68.8%) were male. all patients had sickle cell anemia (hb ss). the variables were studied before and after initiation of hu. results: average number of painful crises was 3.31 before and 1.13 after hu (p = 0.006); average number of red blood cell transfusions was 2.69 before and 0.75 after hu (p = 0.112); average number of acute chest syndrome episodes was 0.19 before and 0.13 after hu (p = 0.705); average number of hospitalizations was 1.94 before and 1.06 after hu (p = 0.155). one patient (6.3%) had hematologic toxicity, two patients (12.5%) had liver toxicity, and three patients (18.6%) had strokes. renal toxicity was not found. there were no malignancies. conclusion: hu significantly reduced the frequency of painful crises in our patients with scd. toxicity was generally acceptable. prospective multicenter, double-blind, placebo-controlled studies are required in order to define the role of hu in pediatric patients with scd.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133